Literature DB >> 33679883

Comprehensive Analysis of Tumor Microenvironment Identified Prognostic Immune-Related Gene Signature in Ovarian Cancer.

Na Li1,2,3, Biao Li1,2,3, Xianquan Zhan1,2,3,4.   

Abstract

BACKGROUND: Accumulating evidence demonstrated that tumor microenvironmental cells played important roles in predicting clinical outcomes and therapeutic efficacy. We aimed to develop a reliable immune-related gene signature for predicting the prognosis of ovarian cancer (OC).
METHODS: Single sample gene-set enrichment analysis (ssGSEA) of immune gene-sets was used to quantify the relative abundance of immune cell infiltration and develop high- and low-abundance immune subtypes of 308 OC samples. The presence of infiltrating stromal/immune cells in OC tissues was calculated as an estimate score. We estimated the correlation coefficients among the immune subtype, clinicopathological feature, immune score, distribution of immune cells, and tumor mutation burden (TMB). The differentially expressed immune-related genes between high- and low-abundance immune subtypes were further used to construct a gene signature of a prognostic model in OC with lasso regression analysis.
RESULTS: The ssGSEA analysis divided OC samples into high- and low-abundance immune subtypes based on the abundance of immune cell infiltration, which was significantly related to the estimate score and clinical characteristics. The distribution of immune cells was also significantly different between high- and low-abundance immune subtypes. The correlation analysis showed the close relationship between TMB and the estimate score. The differentially expressed immune-related genes between high- and low-abundance immune subtypes were enriched in multiple immune-related pathways. Some immune checkpoints (PDL1, PD1, and CTLA-4) were overexpressed in the high-abundance immune subtype. Furthermore, the five-immune-related-gene-signature prognostic model (CCL18, CXCL13, HLA-DOB, HLA-DPB2, and TNFRSF17)-based high-risk and low-risk groups were significantly related to OC overall survival.
CONCLUSION: Immune-related genes were the promising predictors of prognosis and survival, and the comprehensive landscape of tumor microenvironmental cells of OC has potential for therapeutic schedule monitoring.
Copyright © 2021 Li, Li and Zhan.

Entities:  

Keywords:  clinical characteristics; distribution of immune cells; distribution of tumor mutation burden; immune-related-gene-signature; ovarian cancer

Year:  2021        PMID: 33679883      PMCID: PMC7928403          DOI: 10.3389/fgene.2021.616073

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  49 in total

Review 1.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

2.  Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.

Authors:  Qiong Wu; Lei Wang; Huagen Wei; Ben Li; Jiaming Yang; Zilin Wang; Jianfeng Xu; You Lang Zhou; Bo Zhang
Journal:  Int Immunopharmacol       Date:  2020-04-08       Impact factor: 4.932

Review 3.  [The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis].

Authors:  Patrycja Piętak; Natalia Pietrzyk; Anna Pawłowska; Dorota Suszczyk; Wiesława Bednarek; Jan Kotarski; Iwona Wertel
Journal:  Wiad Lek       Date:  2018

4.  Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.

Authors:  Ting-Chao Chou; Huajin Dong; Xiuguo Zhang; William P Tong; Samuel J Danishefsky
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

Review 5.  Cancer and the Immune System: The History and Background of Immunotherapy.

Authors:  Maura Abbott; Yelena Ustoyev
Journal:  Semin Oncol Nurs       Date:  2019-09-13       Impact factor: 2.315

6.  Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.

Authors:  Juan Xiao; Manman Xu; Teng Hou; Yongwen Huang; Chenlu Yang; Jundong Li
Journal:  Mol Med Rep       Date:  2015-05-14       Impact factor: 2.952

7.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Authors:  Etienne Becht; Nicolas A Giraldo; Laetitia Lacroix; Bénédicte Buttard; Nabila Elarouci; Florent Petitprez; Janick Selves; Pierre Laurent-Puig; Catherine Sautès-Fridman; Wolf H Fridman; Aurélien de Reyniès
Journal:  Genome Biol       Date:  2016-10-20       Impact factor: 13.583

8.  Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer.

Authors:  Ting Wang; Zhiwei Zhang; Huaixin Xing; Li Wang; Guoxiang Zhang; Na Yu; Junzhi Wang; Wei Guo; Jie Jiang
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

9.  Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.

Authors:  Cornelia Siebenkäs; Katherine B Chiappinelli; Angela A Guzzetta; Anup Sharma; Jana Jeschke; Rajita Vatapalli; Stephen B Baylin; Nita Ahuja
Journal:  PLoS One       Date:  2017-06-16       Impact factor: 3.240

Review 10.  Ovarian Cancer Immunotherapy: Turning up the Heat.

Authors:  Eleonora Ghisoni; Martina Imbimbo; Stefan Zimmermann; Giorgio Valabrega
Journal:  Int J Mol Sci       Date:  2019-06-15       Impact factor: 5.923

View more
  4 in total

1.  Ovarian Cancer Risk Scores Based on Immune-Related Pseudogenes to Predict Overall Survival and Guide Immunotherapy and Chemotherapy.

Authors:  Jie Zhao; Rixiang Zhao; Xiaocen Wei; Xiaojing Jiang; Fan Su
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-08       Impact factor: 2.629

2.  Integration of Transcriptome and Epigenome to Identify and Develop Prognostic Markers for Ovarian Cancer.

Authors:  Can Xu; Wei Cao
Journal:  J Oncol       Date:  2022-08-30       Impact factor: 4.501

3.  CD8+ T cell-associated genes MS4A1 and TNFRSF17 are prognostic markers and inhibit the progression of colon cancer.

Authors:  Ye Song; Zhipeng Zhang; Bo Zhang; Weihui Zhang
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

Review 4.  Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.

Authors:  Ching-Hung Hsieh; Cheng-Zhe Jian; Liang-In Lin; Guan-Sian Low; Ping-Yun Ou; Chiun Hsu; Da-Liang Ou
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.